Bioimpedance phase angle indicates catabolism in Type 2 diabetes.

Assessing cellular health in diabetes remains a challenge. While bioimpedance phase angle has been linked to body cell mass, its relevance in diabetes is unclear. Prior research has shown that phase angle correlates with cellular integrity and function. However, no prior work had resolved whether this metric reflects catabolic states in diabetic populations. This gap motivated a closer look at how phase angle might serve as a diagnostic marker. Establishing a link between phase angle and diabetes-related catabolism could improve patient monitoring. Researchers have already known that bioimpedance reflects tissue composition, but its role in diabetes is uncertain. That uncertainty drove the need for a study focused on Type 2 diabetes patients. This paper aims to clarify whether phase angle can indicate catabolism in this population.

The study aimed to evaluate if bioimpedance phase angle can indicate catabolism in Type 2 diabetes patients. Specifically, it sought to determine if phase angle measurements differ between diabetic patients and controls. The researchers also wanted to assess whether therapy type influences phase angle values. This work addresses a gap in understanding how cellular health metrics apply to diabetes. By comparing phase angles across therapy groups, the study tests the hypothesis that phase angle reflects metabolic state. The motivation stems from the need for non-invasive biomarkers of catabolism in diabetes. The authors propose that phase angle could serve as a proxy for cellular health in this population. This paper contributes to the broader goal of improving diabetes monitoring through bioimpedance analysis.

The study used a cross-sectional design with 182 Type 2 diabetes patients and 107 controls. Participants were matched by age and BMI to reduce confounding variables. Bioimpedance phase angle was measured at three frequencies: 5, 50, and 100 kHz. Multifrequency bioimpedance analysis allowed comparison of phase angles across different frequencies. Researchers compared phase angles among three therapy groups: untreated, oral drug-treated, and insulin-treated. Total body potassium was used as a reference for body cell mass. Phase angle ratios were calculated to assess discrimination between groups. Statistical analysis included correlation tests and comparisons between groups.

The phase angle at 100 kHz showed the strongest correlation with total body potassium (r = 0.70, P = 0.001). This frequency provided better discrimination between diabetic patients and controls than 50 kHz. Diabetic patients had lower phase angles at 100 kHz than controls (men: 5.2° vs. 4.5°, P < 0.0001; women: 4.8° vs. 4.2°, P < 0.0001). At 50 kHz, phase angles were also lower in diabetic patients (men: 5.9° vs. 5.3°, P < 0.0001; women: 5.4° vs. 4.8°, P = 0.0001). However, at 5 kHz, diabetic patients had higher phase angles than controls (men: 2.0° vs. 2.6°, P = 0.0001; women: 2.3° vs. 3.0°, P = 0.00001). Phase angle ratios (5 kHz/50 kHz and 5 kHz/100 kHz) showed stronger discrimination than individual phase angles. The phase angle at 100 kHz correlated inversely with disease duration and HbA1c levels in both men and women. No differences in phase angles were observed among the three therapy groups.

The authors suggest that phase angle at 100 kHz is a promising indicator of catabolic state in Type 2 diabetes. They propose that this measurement reflects cellular health and function in diabetic populations. The findings suggest that phase angle at 100 kHz correlates with total body potassium and disease markers. The authors note that phase angle ratios provide better discrimination between diabetic and control groups than individual values. They suggest that phase angle at 100 kHz may serve as a non-invasive biomarker for assessing catabolism. The study does not assign essentiality to any specific therapy type in influencing phase angle. The authors propose that further research could explore the clinical utility of phase angle measurements. They conclude that phase angle at 100 kHz has potential as a diagnostic tool in diabetes management.